KRPIA expressed serious concern in a comment on the 10th that the HIRA was confirmed to evaluate the cost effectiveness at 80% of the lowest A7 adjustment price when asked about the cost-effectiveness criteria of Kim Mi-ae, a member of the National Assembly. KRPIA said, "In the course of discussions with the HIRA, we have repeatedly expressed opinions that uncertainties arising from the application of the risk-sharing system in A7 countries should be flexibly evaluated according to the characteristics of each drug."

In addition, it pointed out, "If the figure of 80% for which the basis for calculation is not clear is applied collectively, access to drugs subject to PE exemption, which are limited to pat